{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:18:41Z","timestamp":1788250721128,"version":"build-2803163510"},"reference-count":43,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA265735\u201001"],"award-info":[{"award-number":["1U01CA265735\u201001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We aimed to evaluate the real\u2010world (RW) efficacy and safety of standard\u2010of\u2010care CART versus TCE therapies in relapsed\/refractory myeloma (RRMM), to assess utilization, outcomes, and tolerability of these therapies in a RW oncology in the US. Data were derived from the US\u2010based, electronic health record\u2010derived deidentified Flatiron Health Research Database, 2021\u20132024. A total of 419 patients (CART\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009220; TCE\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009199) with a confirmed diagnosis of myeloma who received CART or TCE as a standard\u2010of\u2010care treatment after at least 2 prior lines of therapy were included. Patients in the CART cohort were younger, had better ECOG PS, and a higher receipt of a prior autologous stem cell transplant versus bispecific TCE cohort. In CART versus TCE cohort, the overall response rates (ORR) were 83.3% versus 66.3%, median duration of response 7.9\u2009months versus 4.3\u2009months, progression free survival (PFS) 13.6\u2009months versus 10.5\u2009months, and overall survival (OS) of 29.8\u2009months versus 21.9\u2009months, respectively. A higher percentage of hematologic toxicity, infections, and cytokine release syndrome (CRS) were noted in the CART versus TCE cohort. This study provides insights on the RW effectiveness of CART versus TCE in the treatment of RRMM; highlights the differences in patient selection, clinical responses, treatment duration, and toxicity profiles.\n                  <\/jats:p>","DOI":"10.1111\/ejh.70304","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:05:31Z","timestamp":1788249931000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Efficacy and Safety of Standard\u2010of\u2010Care Chimeric Antigen Receptor T\u2010Cell (\n                    <scp>CART<\/scp>\n                    ) and Bispecific T\u2010Cell Engager (\n                    <scp>TCE<\/scp>\n                    ) Therapies in Relapsed\/Refractory Multiple Myeloma (\n                    <scp>RRMM<\/scp>\n                    )"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4218","authenticated-orcid":false,"given":"Poy","family":"Theprungsirikul","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale School of Medicine  Connecticut USA"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center Yale University  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4174","authenticated-orcid":false,"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center Yale University  Connecticut USA"},{"name":"Department of Chronic Disease Epidemiology Yale School of Public Health  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-9556","authenticated-orcid":false,"given":"Su\u2010Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery Washington University in St. Louis School of Medicine  Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noffar","family":"Bar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale School of Medicine  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-0654","authenticated-orcid":false,"given":"Sabrina","family":"Browning","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale School of Medicine  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale School of Medicine  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5784","authenticated-orcid":false,"given":"Shi\u2010Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center Yale University  Connecticut USA"},{"name":"Department of Chronic Disease Epidemiology Yale School of Public Health  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-077X","authenticated-orcid":false,"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale School of Medicine  Connecticut USA"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center Yale University  Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010024\u201000529\u2010"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00135\u20105"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115674"},{"key":"e_1_2_10_6_1","unstructured":"Bristol\u2010Myers Squibb \u201cABECMA (idecabtagene vicleucel) \u201d(2025) https:\/\/www.fda.gov\/media\/147055\/download."},{"key":"e_1_2_10_7_1","unstructured":"Janssen Biotech Inc. \u201cCARVYKTI (ciltacabtagene autoleucel) \u201d(2025) https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"e_1_2_10_8_1","unstructured":"Janssen Biotech Inc. \u201cTECVAYLI (teclistamab\u2010cqyv) \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf."},{"key":"e_1_2_10_9_1","unstructured":"Pfizer Inc. \u201cELREXFIO (elranatamab\u2010bcmm) \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_2_10_11_1","unstructured":"Janssen Biotech Inc. \u201cTALVEY (Talquetamab\u2010tgvs) \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100435\u20107"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001531\u20102"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00933\u20108"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967720.61024.68"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00690"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002589\u2010w"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002528\u20109"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00385\u20105"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285768"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005482"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28877"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000886\u20108"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010181762"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283888"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"issue":"2","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1016\/j.jtct.2023.12.539","article-title":"Carvykti Real\u2010World Outcomes Across Sarah Cannon Network","volume":"30","author":"Gregory T.","year":"2024","journal-title":"Transplant and Cellular Therapy"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010190793"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002154\u20105"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001003\u2010z"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001259\u2010z"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001200\u2010w"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010210976"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_10_43_1","unstructured":"National Cancer Institute \u201cCTCAE v5.0 \u201d(2017) https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19532"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:05:33Z","timestamp":1788249933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":43,"alternative-id":["10.1111\/ejh.70304"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70304","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2026-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70304"}}